Summary of the updated recommendations from the Public Health Service Task Force to reduce perinatal human immunodeficiency virus-1 transmission in the United States.
Within the last decade, substantial advances have been made in the treatment of human immunodeficiency virus (HIV)-infected pregnant women and in the prevention of perinatal HIV-1 transmission, and recommendations for care continually change. Within this rapidly evolving field, the Public Health Service Task Force Perinatal HIV Guidelines Working Group, which is composed of pediatric and obstetric experts in HIV infection, community representatives, and federal agency representatives, currently meets by monthly conference calls to review new data related to prevention of mother-to-child HIV transmission and management of women with HIV infection. This group periodically issues updates to their guidelines, "Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States," which are available on the HIV/AIDS Treatment Information Service Web site (http://www.hivatis.org).
D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission*; D015497:HIV-1; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D011634:Public Health; D014481:United States